Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA; Alliance for Clinical Trials In Oncology (ACTION). Rizzieri DA, et al. Br J Haematol. 2014 Apr;165(1):102-11. doi: 10.1111/bjh.12736. Epub 2014 Jan 15. Br J Haematol. 2014. PMID: 24428673 Free PMC article.
Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.
Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Rizzieri DA, et al. J Clin Oncol. 1999 Oct;17(10):3064-74. doi: 10.1200/JCO.1999.17.10.3064. J Clin Oncol. 1999. PMID: 10506601 Clinical Trial.
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ, Vredenburgh JJ, Gasparetto C, Long GD, Anderson E, Foster T, Toaso B, Adams D, Niedzwiecki D, Gockerman JP. Rizzieri DA, et al. Cancer. 2004 Jun 1;100(11):2408-14. doi: 10.1002/cncr.20245. Cancer. 2004. PMID: 15160345 Free article. Clinical Trial.
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao N, Gockerman JP, Garcia RA, Rizzieri DA. Shea TC, et al. Among authors: rizzieri da. Leuk Lymphoma. 2009 May;50(5):741-8. doi: 10.1080/10428190902853136. Leuk Lymphoma. 2009. PMID: 19358012 Clinical Trial.
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
Crout CA, Koh LP, Gockerman JP, Moore JO, Decastro C, Long GD, Diehl L, Gasparetto C, Niedzwiecki D, Edwards J, Prosnitz L, Horwitz M, Chute J, Morris A, Davis P, Beaven A, Chao NJ, Ali-Osman F, Rizzieri DA. Crout CA, et al. Among authors: rizzieri da. Cancer Invest. 2010 Jul;28(6):654-60. doi: 10.3109/07357901003631015. Cancer Invest. 2010. PMID: 20521909 Clinical Trial.
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
Farag SS, Maharry K, Zhang MJ, Pérez WS, George SL, Mrózek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ; Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B. Farag SS, et al. Among authors: rizzieri da. Biol Blood Marrow Transplant. 2011 Dec;17(12):1796-803. doi: 10.1016/j.bbmt.2011.06.005. Epub 2011 Jun 21. Biol Blood Marrow Transplant. 2011. PMID: 21699879 Free PMC article. Clinical Trial.
248 results